{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:22:18Z","timestamp":1780496538001,"version":"3.54.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"136 Revitalization Medical Project Construction Funds"},{"name":"Foundation of Evidence-based Nursing of Peking University","award":["XZSR-2022-12"],"award-info":[{"award-number":["XZSR-2022-12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nonalcoholic fatty liver disease (NAFLD) is a prevalent chronic liver disorder worldwide. According to several previous studies, the treatment of patients with NAFLD using medicinal and food-homologous substances has consistent effects on the levels of blood lipids and blood glucose and liver function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This systematic review was conducted to investigate the impact of medicinal and food homologous substances on blood lipid and glucose levels as well as liver function in patients with NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A thorough search was conducted in eight databases, including China Science and Technology Journal Database (VIP), Chinese National Knowledge Infrastructure(CNKI), China Biomedical Literature Database (SinoMed), Wanfang Database, PubMed, Cochrane Library, Web of Science and Embase, for articles published from database inception until June 24, 2023. The methodological quality of the included studies was evaluated utilizing Cochrane Randomized Trial Risk Bias Tool, Edition 2 and GRADE methodology for assessment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 13 randomized controlled trials, involving 829 patients with NAFLD, were included in the analysis, these studies included a total of 9 medicinal and food homologous substances. In the 13 studies, hawthorn (2), sea buckthorn (1), ginger (2), turmeric (4) (1 with chicory seeds), cinnamon (1), cardamom (1), purslane (1) and saffron (1) were included. The results of the included studies showed that medicinal and food homologous substances could improve high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TGs), fasting blood glucose (FBG) and liver enzyme levels in patients with NAFLD to a certain extent, but the effect of turmeric on TC, liver enzyme levels is controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In patients with NAFLD, dietary intervention using medicinal and food homologous substances can ameliorate blood lipid and blood glucose levels and liver enzymes to some extent. In clinical work, medicinal and food homologous substances can be used to provide patients with NAFLD with a safe and effective dietary plan to help prevent and treat disease onset and progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-023-01900-5","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T10:03:00Z","timestamp":1693303380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The effects of medicinal and food homologous substances on blood lipid and blood glucose levels and liver function in patients with nonalcoholic fatty liver disease: a systematic review of randomized controlled trials"],"prefix":"10.1186","volume":"22","author":[{"given":"Qian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"6","key":"1900_CR1","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/hep.22868","volume":"49","author":"K David","year":"2009","unstructured":"David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB, et al. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49(6):1904\u201312.","journal-title":"Hepatology"},{"issue":"5","key":"1900_CR2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","volume":"67","author":"AM Allen","year":"2018","unstructured":"Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology. 2018;67(5):1726\u201336.","journal-title":"Hepatology"},{"issue":"5","key":"1900_CR3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S2468-1253(20)30091-1","volume":"5","author":"The Lancet Gastroenterology H","year":"2020","unstructured":"The Lancet Gastroenterology H. Redefining non-alcoholic fatty liver disease: what\u2019s in a name? Lancet Gastroenterol Hepatol. 2020;5(5):419.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"1900_CR4","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3748\/wjg.v20.i7.1712","volume":"20","author":"KJ Schwenger","year":"2014","unstructured":"Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(7):1712\u201323.","journal-title":"World J Gastroenterol"},{"key":"1900_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2023.100229","volume":"17","author":"N Nasiri-Ansari","year":"2023","unstructured":"Nasiri-Ansari N, Kassi E. Editorial: special issue: non-alcoholic fatty liver disease: from molecular basis to therapeutic advances. Metabol Open. 2023;17: 100229.","journal-title":"Metabol Open"},{"issue":"12","key":"1900_CR6","first-page":"1363","volume":"29","author":"ZT Zhou","year":"2020","unstructured":"Zhou ZT, Deng LM, Hu LJ, Ren Q, Zhang LY, Li Z. Recent advances in research on targets and drugs for treatment of nonalcoholic fatty liver disease. Chin New Drug. 2020;29(12):1363\u201374.","journal-title":"Chin New Drug"},{"issue":"10290","key":"1900_CR7","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"issue":"11","key":"1900_CR8","first-page":"2772","volume":"33","author":"L Zhang","year":"2022","unstructured":"Zhang L, Chen D, Huang MA. An analysis of Li Shizhen\u2019s contribution to the homology of medicine and food. Lishizhen Med Mate Med Res. 2022;33(11):2772\u20135.","journal-title":"Lishizhen Med Mate Med Res"},{"key":"1900_CR9","first-page":"218","volume":"04","author":"YJ Guo","year":"2001","unstructured":"Guo YJ. The therapeutic effect of non-nutrients in food. Chin J Nat Med. 2001;04:218\u20139.","journal-title":"Chin J Nat Med"},{"key":"1900_CR10","unstructured":"Ministry of Health of the People's Republic of China. Notice of the Ministry of Health on Further Regulating the Management of Raw Materials of Health Food (Health Law Supervision [2002] No.51. http:\/\/www.nhc.gov.cn\/zwgk\/wtwj\/201304\/e33435ce0d894051b15490aa3219cdc4.shtml."},{"issue":"10","key":"1900_CR11","first-page":"6123","volume":"37","author":"HH Liu","year":"2022","unstructured":"Liu HH, Zeng HM, Zhang GC, Sun XS. Analysis ofthe changes of description of food and drug homologous herbs from the perspective of psychical transmutation. China J Tradit Chin Med Pharm. 2022;37(10):6123\u20136.","journal-title":"China J Tradit Chin Med Pharm"},{"issue":"3","key":"1900_CR12","first-page":"309","volume":"36","author":"G Cui","year":"2020","unstructured":"Cui G, Bai J, Miao L, et al. Effects of Fructus Lycii on T helper cell 17 and related cytokines in non-alcoholic fatty liver disease. Chin J Clin Pharmacol. 2020;36(3):309\u201312.","journal-title":"Chin J Clin Pharmacol"},{"issue":"3","key":"1900_CR13","first-page":"879","volume":"53","author":"H Li","year":"2022","unstructured":"Li H, Pang D, Liu Y, et al. Effects of Cinnamon cassia free phenolic extract on nonalcoholic hepatocyte steatosis. J South Argicult. 2022;53(3):879\u201390.","journal-title":"J South Argicult"},{"key":"1900_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"issue":"6","key":"1900_CR15","first-page":"24","volume":"27","author":"J Yu","year":"2017","unstructured":"Yu J. Catalogue of homologous raw materials of medicine and food (Edition). Oral Care Ind. 2017;27(6):24\u20138.","journal-title":"Oral Care Ind"},{"key":"1900_CR16","unstructured":"State Health Commission, State Administration for Market Regulation. Notice on Piloting the material management of nine substances including Codonopsis codonopsis, which are traditionally both food and medicinal herbs (Guowei Food Letter (2019) No.311. http:\/\/www.nhc.gov.cn\/sps\/s7885\/202001\/1ec2cca04146450d9b14acc2499d854f.shtml."},{"key":"1900_CR17","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org\/handbook."},{"issue":"7","key":"1900_CR18","first-page":"934","volume":"20","author":"MY Liu","year":"2022","unstructured":"Liu MY, Wang CY, Zhang X, Zhu RF, Cao Y, Feng YQ, et al. Effect of Tartary buckwheat and sea buckthorn vinegar Drink combined on patients with metabolic-related fatty liver disease [J]. Chin Gen Pract Nurs. 2022;20(7):934\u20138.","journal-title":"Chin Gen Pract Nurs"},{"key":"1900_CR19","unstructured":"Liu LM. Experimental observation of Taiji soft power ball combined with Hawthorn tea in patients with NAFLD. Chin Commun Doctors. 2012;14(4):272\u20133."},{"key":"1900_CR20","unstructured":"Tao ZH. Pharmacologic analysis of long-term high dose single Herb Hawthorn on blood lipids in patients with nonalcoholic fatty liver disease caused by high fat diet. Guangming J Chin Med. 2021;36(12):1991\u20133."},{"key":"1900_CR21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CEG.S234698","volume":"13","author":"R Rafie","year":"2020","unstructured":"Rafie R, Hosseini SA, Hajiani E, Malehi AS, Mard SA. Effect of ginger powder supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. Clin Exp Gastroenterol. 2020;13:35\u201345.","journal-title":"Clin Exp Gastroenterol"},{"key":"1900_CR22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12906-019-2465-0","volume":"19","author":"M Daneshi-Maskooni","year":"2019","unstructured":"Daneshi-Maskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badri-Fariman M, et al. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial. Bmc Complement Altern Med. 2019;19:59.","journal-title":"Bmc Complement Altern Med"},{"issue":"1","key":"1900_CR23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13098-021-00731-7","volume":"13","author":"M Jarhahzadeh","year":"2021","unstructured":"Jarhahzadeh M, Alavinejad P, Farsi F, Husain D, Rezazadeh A. The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: a randomized double blind clinical trial. Diabetol Metab Syndr. 2021;13(1):112.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"1900_CR24","first-page":"e34897","volume":"16","author":"M Rahimlou","year":"2016","unstructured":"Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Hepa Monthly. 2016;16(1):e34897.","journal-title":"Hepa Monthly"},{"issue":"5\u20136","key":"1900_CR25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1024\/0300-9831\/a000568","volume":"89","author":"A Ghaffari","year":"2019","unstructured":"Ghaffari A, Rafraf M, Navekar R, Sepehri B, Asghari-Jafarabadi M, Ghavami SM. Turmeric and chicory seed have beneficial effects on obesity markers and lipid profile in non-alcoholic fatty liver disease (NAFLD). Int J Vitam Nutr Res. 2019;89(5\u20136):293\u2013302.","journal-title":"Int J Vitam Nutr Res"},{"key":"1900_CR26","doi-asserted-by":"crossref","unstructured":"Ghaffari A, Rafraf M, Navekar R, Sepehri B, Asghari-Jafarabadi M, Ghavami SM. Effects of turmeric on homocysteine and Fetuin-A in patients with nonalcoholic fatty liver disease: a randomized double-blind placebo-controlled study. Iran Red Cresc Med J. 2017;19(4):e43193.","DOI":"10.5812\/ircmj.43193"},{"issue":"4","key":"1900_CR27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/07315724.2016.1267597","volume":"36","author":"R Navekar","year":"2017","unstructured":"Navekar R, Rafraf M, Ghaffari A, Asghari-Jafarabadi M, Khoshbaten M. Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases. J Am Coll Nutr. 2017;36(4):261\u20137.","journal-title":"J Am Coll Nutr"},{"issue":"2","key":"1900_CR28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nutres.2013.11.005","volume":"34","author":"F Askari","year":"2014","unstructured":"Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 2014;34(2):143\u20138.","journal-title":"Nutr Res"},{"issue":"5","key":"1900_CR29","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/ptr.6342","volume":"33","author":"A Gheflati","year":"2019","unstructured":"Gheflati A, Adelnia E, Nadjarzadeh A. The clinical effects of purslane (Portulaca oleracea) seeds on metabolic profiles in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. Phytother Res. 2019;33(5):1501\u20139.","journal-title":"Phytother Res"},{"issue":"12","key":"1900_CR30","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1002\/ptr.6791","volume":"34","author":"FK Pour","year":"2020","unstructured":"Pour FK, Aryaeian N, Mokhtare M, Mirnasrollahi Parsa RS, Jannani L, Agah S, et al. The effect of saffron supplementation on some inflammatory and oxidative markers, leptin, adiponectin, and body composition in patients with nonalcoholic fatty liver disease: A double-blind randomized clinical trial. Phytother Res. 2020;34(12):3367\u201378.","journal-title":"Phytother Res"},{"issue":"11","key":"1900_CR31","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1002\/ptr.7596","volume":"36","author":"Y Geng","year":"2022","unstructured":"Geng Y, Wang J, Chen K, Li Q, Ping Z, Xue R, et al. Effects of sea buckthorn (Hippophae rhamnoides L.) on factors related to metabolic syndrome: a systematic review and meta-analysis of randomized controlled trial. Phytother Res. 2022;36(11):4101\u201314.","journal-title":"Phytother Res"},{"issue":"1","key":"1900_CR32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.imr.2018.07.004","volume":"8","author":"F Mansour-Ghanaei","year":"2019","unstructured":"Mansour-Ghanaei F, Pourmasoumi M, Hadi A, Joukar F. Efficacy of curcumin\/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: a systematic review of randomized controlled trials. Integr Med Res. 2019;8(1):57\u201361.","journal-title":"Integr Med Res"},{"issue":"3","key":"1900_CR33","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/ptr.7390","volume":"36","author":"M Samadi","year":"2022","unstructured":"Samadi M, Moradinazar M, Khosravy T, Soleimani D, Jahangiri P, Kamari N. A systematic review and meta-analysis of preclinical and clinical studies on the efficacy of ginger for the treatment of fatty liver disease. Phytother Res. 2022;36(3):1182\u201393.","journal-title":"Phytother Res"},{"key":"1900_CR34","doi-asserted-by":"crossref","first-page":"109734","DOI":"10.1016\/j.biopha.2019.109734","volume":"126","author":"Y Li","year":"2020","unstructured":"Li Y, Wang C, Jin Y, Chen H, Cao M, Li W, et al. Huang-Qi San improves glucose and lipid metabolism and exerts protective effects against hepatic steatosis in high fat diet-fed rats. Biomed Pharmacother. 2020;126:109734.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1900_CR35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12906-016-1381-9","volume":"16","author":"M Mashmoul","year":"2016","unstructured":"Mashmoul M, Azlan A, Mohtarrudin N, Mohd Yusof BN, Khaza\u2019ai H, Khoo HE, et al. Protective effects of saffron extract and crocin supplementation on fatty liver tissue of high-fat diet-induced obese rats. BMC Complement Altern Med. 2016;16(1):401.","journal-title":"BMC Complement Altern Med"},{"key":"1900_CR36","first-page":"82","volume":"10","author":"TY Fang","year":"2009","unstructured":"Fang TY. Iranian traditional medicine is widely used. Chinese Health. 2009;10:82\u201382.","journal-title":"Chinese Health"},{"key":"1900_CR37","first-page":"565","volume":"37","author":"SF Han","year":"2023","unstructured":"Han SF, Feng YQ, Gao WQ. Theoretical model of non\u2043nutrient diet therapy for prevention and treatment of chronic diseases. Chin Nurs Res. 2023;37:565.","journal-title":"Chin Nurs Res"},{"issue":"01","key":"1900_CR38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13020-022-00643-2","volume":"17","author":"YY Wang","year":"2022","unstructured":"Wang YY. Observation of blood lipid, blood glucose and liver function in patients with nonalcoholic fatty liver disease. China Pract Med. 2022;17(01):89\u201391.","journal-title":"China Pract Med"},{"issue":"7","key":"1900_CR39","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/17461391.2019.1571114","volume":"19","author":"P Farzanegi","year":"2019","unstructured":"Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M, Azarbayjani MA. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. Eur J Sport Sci. 2019;19(7):994\u20131003.","journal-title":"Eur J Sport Sci"},{"issue":"01","key":"1900_CR40","first-page":"114","volume":"27","author":"XJ Xu","year":"2016","unstructured":"Xu XJ, Zhang XF, Xu DQ, Chen YM. Research progress in the regulation of blood lipid by flavonoids. China Pharm. 2016;27(01):114\u20137.","journal-title":"China Pharm"},{"key":"1900_CR41","first-page":"5","volume":"01","author":"JJ Guo","year":"2008","unstructured":"Guo JJ, Yang XF. Research progress of the protective effect of flavanoids on experimental liver injury of animals. Chin Pharmacol Bull. 2008;01:5\u201310.","journal-title":"Chin Pharmacol Bull"},{"issue":"12","key":"1900_CR42","volume":"46","author":"H Li","year":"2022","unstructured":"Li H, Gao L, Shao H, Li B, Zhang C, Sheng H, et al. Elucidation of active ingredients and mechanism of action of hawthorn in the prevention and treatment of atherosclerosis. J Food Biochem. 2022;46(12): e14457.","journal-title":"J Food Biochem"},{"issue":"4","key":"1900_CR43","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1017\/S0007114520002846","volume":"125","author":"QW Zhong","year":"2021","unstructured":"Zhong QW, Wu YY, Xiong F, Liu M, Liu YP, Wang C, et al. Higher flavonoid intake is associated with a lower progression risk of non-alcoholic fatty liver disease in adults: a prospective study. Br J Nutr. 2021;125(4):460\u201370.","journal-title":"Br J Nutr"},{"issue":"06","key":"1900_CR44","first-page":"448","volume":"41","author":"RQ Yao","year":"2021","unstructured":"Yao RQ, Song WQ, Hu XL, Zhang WH. The effects of portulaca oleracea total flavones on non-alcoholic fatty liver disease in mice. Curr Immunol. 2021;41(06):448\u201354.","journal-title":"Curr Immunol"},{"issue":"6","key":"1900_CR45","doi-asserted-by":"crossref","first-page":"835","DOI":"10.5604\/01.3001.0010.5273","volume":"16","author":"RW Hu","year":"2017","unstructured":"Hu RW, Carey EJ, Lindor KD, Tabibian JH. Curcumin in hepatobiliary disease: Pharmacotherapeutic properties and emerging potential clinical applications. Ann Hepatol. 2017;16(6):835\u201341.","journal-title":"Ann Hepatol"},{"issue":"3","key":"1900_CR46","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.fct.2010.01.003","volume":"48","author":"AS Cho","year":"2010","unstructured":"Cho AS, Jeon SM, Kim MJ, Yeo J, Seo KI, Choi MS, et al. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol. 2010;48(3):937\u201343.","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"1900_CR47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/nyas.13375","volume":"1398","author":"J Wang","year":"2017","unstructured":"Wang J, Ke W, Bao R, Hu X, Chen F. Beneficial effects of ginger Zingiber officinale Roscoe on obesity and metabolic syndrome: a review. Ann N Y Acad Sci. 2017;1398(1):83\u201398.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1900_CR48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/nu7020999","volume":"7","author":"TF Tzeng","year":"2015","unstructured":"Tzeng TF, Liou SS, Chang CJ, Liu IM. 6-gingerol protects against nutritional steatohepatitis by regulating key genes related to inflammation and lipid metabolism. Nutrients. 2015;7(2):999\u20131020.","journal-title":"Nutrients"},{"issue":"10","key":"1900_CR49","first-page":"1831","volume":"31","author":"KF Xian","year":"2019","unstructured":"Xian KF, Yin H. Research progress on chemical constituents and pharmacological activities of Amomum plants. Nat Prod Res Dev. 2019;31(10):1831\u20136.","journal-title":"Nat Prod Res Dev"},{"issue":"3","key":"1900_CR50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092358","volume":"9","author":"T Sartorius","year":"2014","unstructured":"Sartorius T, Peter A, Schulz N, Drescher A, Bergheim I, Machann J, et al. Cinnamon extract improves insulin sensitivity in the brain and lowers liver fat in mouse models of obesity. PLoS ONE. 2014;9(3): e92358.","journal-title":"PLoS ONE"},{"issue":"11","key":"1900_CR51","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14744","volume":"75","author":"V Musazadeh","year":"2021","unstructured":"Musazadeh V, Dehghan P, Saleh-Ghadimi S, Farhangi MA. Omega 3-rich Camelina sativa oil in the context of a weight loss program improves glucose homeostasis, inflammation and oxidative stress in patients with NAFLD: A randomised placebo-controlled clinical trial. Int J Clin Pract. 2021;75(11): e14744.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"1900_CR52","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/MEG.0000000000002297","volume":"34","author":"V Musazadeh","year":"2022","unstructured":"Musazadeh V, Dehghan P, Khoshbaten M. Efficacy of omega-3-rich Camelina sativa on the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2022;34(5):537\u201345.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1900_CR53","unstructured":"Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019;70(6):809\u201324."},{"key":"1900_CR54","doi-asserted-by":"crossref","first-page":"7092151","DOI":"10.1155\/2019\/7092151","volume":"2019","author":"S Steven","year":"2019","unstructured":"Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Jimenez MTB, et al. Vascular inflammation and oxidative stress: major triggers for cardiovascular disease. Oxid Med Cell Longev. 2019;2019:7092151.","journal-title":"Oxid Med Cell Longev"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-023-01900-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-023-01900-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-023-01900-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:29:42Z","timestamp":1700490582000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-023-01900-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1900"],"URL":"https:\/\/doi.org\/10.1186\/s12944-023-01900-5","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"9 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors unanimously agreed to publish the manuscript. What this study did was not covered by previous studies. This manuscript will not be published elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}